Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone / 100 mg proguanil tablet for oral use. It treats and prevents malaria caused by Plasmodium falciparum and Plasmodium vivax in travelers, expatriates, and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory compliance to ensure product integrity. Malarone is manufactured under EU GMP guidelines and distributed to a global network of healthcare providers.

Malarone (atovaquone/proguanil) is used in the prevention and treatment of malaria, an infectious disease caused by Plasmodium parasites.

- Prevention of malaria (travel prophylaxis): provides protective antimalarial activity for individuals traveling to or residing in endemic areas. - Treatment of acute uncomplicated malaria (Plasmodium falciparum): clears infection and resolves symptoms in patients with confirmed falciparum malaria. - Treatment of acute uncomplicated malaria (Plasmodium vivax): effective against blood‑stage infection of vivax malaria.

Malarone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal pain, or diarrhea. - Headache: mild to moderate intensity. - Dizziness: occasional sensation of light‑headedness. - Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Blood dyscrasias: neutropenia, thrombocytopenia, or anemia. - Hypersensitivity: anaphylaxis or severe allergic reactions.

Before prescribing Malarone, consider the following safety measures.

- Pregnancy: safety not established; use only if benefit outweighs risk. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Concomitant antiretrovirals: may reduce efficacy; assess drug interactions. - Travel to high‑risk areas: ensure adequate prophylactic regimen and adherence. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Malarone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism and reduces plasma concentrations of both components, compromising efficacy. - CYP2C8 inhibitors (e.g., gemfibrozil): increase atovaquone levels, raising risk of toxicity. - Protease inhibitors (e.g., ritonavir): may increase proguanil concentrations, leading to adverse effects.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease atovaquone absorption; separate dosing by at least 2 hours. - Warfarin: proguanil may potentiate anticoagulant effect; monitor INR. - Macrolide antibiotics (e.g., erythromycin): may increase proguanil concentrations; observe for side effects.